home *** CD-ROM | disk | FTP | other *** search
- Document 0651
- DOCN M9490651
- TI The hydroxylamine of sulfamethoxazole and adverse reactions in patients
- with acquired immunodeficiency syndrome.
- DT 9411
- AU Lee BL; Delahunty T; Safrin S; Department of Medicine, University of
- California, San Francisco.
- SO Clin Pharmacol Ther. 1994 Aug;56(2):184-9. Unique Identifier : AIDSLINE
- MED/94340862
- AB We measured the urine concentrations of sulfamethoxazole,
- sulfamethoxazole hydroxylamine, and N-sulfamethoxazole on days 3 and 10
- in 15 patients with acquired immunodeficiency syndrome treated with a
- combination product of trimethoprim (15 mg/kg/day) and sulfamethoxazole
- (75 mg/kg/day). The percentage of sulfamethoxazole and metabolites
- excreted on days 3 and 10, respectively, were sulfamethoxazole 17.2% +/-
- 11.3% versus 15.6% +/- 8.2%; sulfamethoxazole hydroxylamine 2.6% +/-
- 2.0% versus 5.0% +/- 5.2% (p < 0.05); N-acetylsulfamethoxazole 80.0% +/-
- 12.9% versus 79.8% +/- 11.8%. The percentage of sulfamethoxazole
- hydroxylamine excreted was similar between the eight patients who
- discontinued therapy because of toxicity and the seven patients who did
- not (2.9% +/- 2.3% versus 2.3% +/- 2.0%, p = 0.7). In two patients who
- had major liver toxicity the percentage of sulfamethoxazole
- hydroxylamine excreted was significantly lower than that of the 13
- patients who did not (0.8% +/- 0.1% versus 2.9% +/- 2.0%, p < 0.05).
- This is the first report of the formation and excretion of
- sulfamethoxazole hydroxylamine in patients with acquired
- immunodeficiency syndrome. With 15 patients we were unable to show a
- significant correlation between the percentage of sulfamethoxazole
- hydroxylamine excreted and adverse reactions. However, patients with
- liver toxicity excreted less sulfamethoxazole hydroxylamine.
- DE Administration, Oral Adult AIDS-Related Opportunistic Infections/DRUG
- THERAPY/*URINE Double-Blind Method Drug Therapy, Combination Female
- Human Injections, Intravenous Leucovorin/THERAPEUTIC USE Male Middle
- Age Pneumonia, Pneumocystis carinii/DRUG THERAPY/*URINE
- Sulfamethoxazole/*ANALOGS & DERIVATIVES/METABOLISM/*URINE Support, U.S.
- Gov't, P.H.S. Trimethoprim-Sulfamethoxazole Combination/ADMINISTRATION
- & DOSAGE/ *ADVERSE EFFECTS/THERAPEUTIC USE CLINICAL TRIAL JOURNAL
- ARTICLE RANDOMIZED CONTROLLED TRIAL
-
- SOURCE: National Library of Medicine. NOTICE: This material may be
- protected by Copyright Law (Title 17, U.S.Code).
-
-